clinicaltrialsarena4h
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial
J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.
clinicaltrialsarena5h
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trial
BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.
clinicaltrialsarena21h
Metsera announces positive results in newest Phase IIa GLP-1RA
The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.